文献速递瓣膜外科

非TAVR中心的外科主动脉瓣置换结局:对分级医疗体系的启示

Surgical Aortic Valve Replacement Outcomes in Non-Transcatheter Aortic Valve Replacement Centers: Implications for Tier-Based Systems of Care.
PubMed 文献 · Ann Thorac Surg · 2021-03-24

本研究基于2012至2015年接受SAVR的Medicare受益人,将SAVR医院分为有TAVR项目的A级和无TAVR项目的B级。结果发现A级医院30天和1年死亡率显著低于B级,但低危患者在两级医院均可安全手术。

要点

  • B级医院30天死亡率在非低危患者中显著劣于A级医院
  • 低危患者在两級医院接受SAVR均可获得安全结局
  • 设计主动脉瓣分级医疗体系时应整合质量控制措施

核心结论

  • 低危患者可在A级和B级医院安全接受SAVR而不影响结局。
  • B级医院在非低危患者中30天死亡率显著劣于A级医院。
  • 建立主动脉瓣分级医疗体系时应整合质量控制措施,尤其关注仅行SAVR的医院。

研究设计与样本

  • 回顾性队列研究,纳入2012至2015年接受SAVR的Medicare受益人。
  • SAVR医院分为A级(有TAVR项目)和B级(无TAVR项目)。
  • 采用多变量Cox回归调整生存,并控制项目类型和患者风险特征。
  • 时间依赖分析考虑了研究期间启动TAVR项目的医院。

主要发现

  • 共纳入562家A级医院和485家B级医院。
  • A级医院合并症负担显著高于B级医院(所有P < .05)。
  • A级医院30天死亡率3.2% vs B级4.1%,1年死亡率8.1% vs 9.4%(均P < .05)。
  • 风险分层后,除低危患者外,B级医院30天死亡率在所有风险特征中均显著劣于A级医院(P < .01)。
  • 时间依赖分析中上述发现持续存在,A级医院调整后中期生存率高于B级医院。

临床怎么用

  • 低危患者可选择在B级医院行SAVR,无需强制转诊至A级医院。
  • 对非低危患者,应优先考虑A级医院以降低30天死亡风险。
  • 设计分级医疗体系时需纳入SAVR质量控制指标,尤其针对仅行SAVR的医院。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: With wide expansion of transcatheter aortic valve replacement (TAVR) and dissemination of multidisciplinary-based approaches to care, societies are discussing the implementation of a tier system to valve centers. This study explores the impact of tier-based systems of care on surgical aortic valve replacement (SAVR) outcomes at institutions that perform SAVR only. METHODS: Medicare beneficiaries undergoing SAVR procedures from 2012 to 2015 were included. The SAVR hospitals were stratified into either tier A, valve centers with a TAVR program; or tier B, valve centers without a TAVR program. Adjusted survival, assessed by multivariable Cox regression, controlled for program type and patient risk profile. Time-dependent analysis accounted for hospitals that initiated a TAVR program during the study period. RESULTS: Overall, there were 562 tier A and 485 tier B SAVR hospitals. Tier A hospitals had significantly higher comorbidity burden compared with tier B hospitals (all P < .05) but had significantly lower rates of 30-day mortality (3.2% vs 4.1%) and 1-year mortality (8.1% vs 9.4%; both P < .05). After risk stratification, tier B hospitals had significantly worse 30-day mortality compared with tier A hospitals for all patient risk-profiles, except for the low-risk patients (P < .01). These findings persisted in the time-dependent analysis. Adjusted midterm survival was higher in tier A vs tier B hospitals. CONCLUSIONS: Low-risk patients can safely undergo SAVR in both tier level hospitals without compromising outcomes. Establishment of quality of care measures, especially in the SAVR-only hospitals, remains paramount and should be closely integrated when designing tier-based systems for aortic valve replacement care.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Hirji S, Trager L, Harloff M, et al. Surgical Aortic Valve Replacement Outcomes in Non-Transcatheter Aortic Valve Replacement Centers: Implications for Tier-Based Systems of Care. Ann Thorac Surg. 2021. PMID: 33771501. doi:10.1016/j.athoracsur.2021.02.090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。